PoliticalChina·26 Oct 2026
Head of Hong Kong’s new drug regulator pledges to build trust and innovation
AI-summarized · Neutrality-checked
Dr. Li Zili, the controller of Hong Kong’s new Centre for Medical Products Regulation (CMPR), announced that the agency aimed to establish itself as a globally trusted hub for medical innovation. Li stated that the agency would not function as a smaller version of existing international bodies like the U.S. Food and Drug Administration. He cited Hong Kong’s…
Loading full story…
Sources and context
SCMP
NewspaperCompany ownedHong KongStandards published
Source-level context, not a score for this article. Methodology and evidence · Report outdated information
Know where. Know why.